Andrew Ashe - Dyax Corp Insider

DYAX -- USA Stock  

USD 38.41  38.41  9,223,372,036,855%

  EVP
Mr. Andrew Ashe is Executive Vice President and General Counsel of Dyax Corporationration since March 25 2013. He joined Dyax in 2003 and served as an attorney in our legal department until 2011 when he became our General Counsel. Mr. Ashe now manages the Companys legal intellectual property and compliance activities and also oversees the human resources facilities and information technology departments within Dyax. He also serves as the Companys Corporationrationrate Secretary. Prior to joining Dyax Mr. Ashe practiced law as a corporate attorney at Nutter McClennen Fish and Prince Lobel Tye two private law firms based in Boston Massachusetts. Previously he also worked as a specialist and senior options analyst at the American Stock Exchange in New York
Age: 47  EVP Since 2013      
617-225-2500  http://www.dyax.com
Ashe received his law degree from The George Washington School of Law and a Bachelors in Business Administration from the University of Massachusetts, Amherst.

Andrew Ashe Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (0.06) % which means that it has lost $0.06 on every $100 spent on asset. This is way below average.
The company currently holds 82.17 M in liabilities with Debt to Equity (D/E) ratio of 0.26 which may suggest the company is not taking enough advantage from borrowing. Dyax Corp has Current Ratio of 11.43 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Dyax Corporation, a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema and other plasmakallikreinmediated disorders. Dyax Corp (DYAX) is traded on NASDAQ General Markets in USA. It is located in Burlington, MA and employs 124 people.

Dyax Corp Leadership Team

Thomas Kempner, Independent Director
Henry Blair, Co-Founder, Chairman, Member of Strategy and Science Committee and Member of Compensation Committee
Jennifer Robinson, Associate Director, Investor Relations and Corporate Communications
James Fordyce, Independent Director
Marc Kozin, Independent Director
Mary Gray, Lead Independent Director
Paolo Pucci, Independent Director
George Migausky, CFO, Principal Accounting Officer and Executive VP
Andrew Ashe, Executive VP, General Counsel and Secretary
Abbie Celniker, Independent Director
Ron Cohen, Independent Director
Burt Adelman, Chief Medical Officer, Executive Vice President - Research and Development
Gustav Christensen, CEO and President and Director
Todd Bazemore, Executive Vice President and Chief Commercial Officer
David McLachlan, Independent Director

Stock Performance Indicators

Did you try this?

Run Equity Forecasting Now
   

Equity Forecasting

Use basic forecasting models to generate price predictions and determine price momentum
All  Next Launch Equity Forecasting

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Dyax Corp and SAP SE. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Chance of Distress module to get analysis of equity chance of financial distress in the next 2 years.